Arimidex: Reason for and Effect of Change From Tamoxifen
Phase 4
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer
Female
Breast Cancer
Trial Information
Arimidex: Reason for and Effect of Change From Tamoxifen
Inclusion Criteria:
- Postmenopausal
- Hormone sensitive breast cancer
- Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago
Exclusion Criteria:
- Visceral metastases
- Patients with signs of progression at the moment of changing therapy
- Patients who have used other endocrine treatments for breast cancer besides tamoxifen
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Principal Investigator
AstraZeneca The Netherlands Medical Director, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Netherlands: Dutch Health Care Inspectorate
Study ID:
D5392NL0002
NCT ID:
NCT00246961
Start Date:
July 2004
Completion Date:
Related Keywords:
- Breast Cancer
- Adjuvant
- Breast Neoplasms
Name | Location |
|---|
